keyword
MENU ▼
Read by QxMD icon Read
search

Muscal, jodi

keyword
https://www.readbyqxmd.com/read/27903968/novel-src-abl-tyrosine-kinase-inhibitor-bosutinib-suppresses-neuroblastoma-growth-via-inhibiting-src-abl-signaling
#1
Shayahati Bieerkehazhi, Zhenghu Chen, Yanling Zhao, Yang Yu, Huiyuan Zhang, Sanjeev A Vasudevan, Sarah E Woodfield, Ling Tao, Joanna S Yi, Jodi A Muscal, Jonathan C Pang, Shan Guan, Hong Zhang, Jed G Nuchtern, Hui Li, Huiwu Li, Jianhua Yang
Neuroblastoma (NB) is the most common extracranial solid tumor in children. Aberrant activation of the non-receptor tyrosine kinases Src and c-Abl contributes to the progression of NB. Thus, targeting these kinases could be a promising strategy for NB therapy. In this paper, we report that the potent dual Src/Abl inhibitor bosutinib exerts anti-tumor effects on NB. Bosutinib inhibited NB cell proliferation in a dose-dependent manner and suppressed colony formation ability of NB cells. Mechanistically, bosutinib effectively decreased the activity of Src/Abl and PI3K/AKT/mTOR, MAPK/ERK, and JAK/STAT3 signaling pathways...
November 26, 2016: Oncotarget
https://www.readbyqxmd.com/read/26790674/childhood-and-adolescent-tracheobronchial-mucoepidermoid-carcinoma-mec-a-case-series-and-review-of-the-literature
#2
Sergio Jaramillo, Yesenia Rojas, Bethany J Slater, Michael L Baker, M John Hicks, Jodi A Muscal, Timothy J Vece, David E Wesson, Jed G Nuchtern
Tracheobronchial mucoepidermoid carcinomas (MEC) are rare in the pediatric population with literature limited primarily to case reports. Here we present our institutional experience treating MEC in three patients and review the literature of 142 pediatric cases previously published from 1968 to 2013. Although rare, tracheobronchial MEC should be included in the differential diagnosis in a child with recurrent respiratory symptoms. Conservative surgical management is often sufficient to achieve complete resection and good outcomes...
April 2016: Pediatric Surgery International
https://www.readbyqxmd.com/read/26786851/novel-alk-inhibitor-azd3463-inhibits-neuroblastoma-growth-by-overcoming-crizotinib-resistance-and-inducing-apoptosis
#3
Yongfeng Wang, Long Wang, Shan Guan, Wenming Cao, Hao Wang, Zhenghu Chen, Yanling Zhao, Yang Yu, Huiyuan Zhang, Jonathan C Pang, Sophia L Huang, Yo Akiyama, Yifan Yang, Wenjing Sun, Xin Xu, Yan Shi, Hong Zhang, Eugene S Kim, Jodi A Muscal, Fengmin Lu, Jianhua Yang
ALK receptor tyrosine kinase has been shown to be a therapeutic target in neuroblastoma. Germline ALK activating mutations are responsible for the majority of hereditary neuroblastoma and somatic ALK activating mutations are also frequently observed in sporadic cases of advanced NB. Crizotinib, a first-line therapy in the treatment of advanced non-small cell lung cancer (NSCLC) harboring ALK rearrangements, demonstrates striking efficacy against ALK-rearranged NB. However, crizotinib fails to effectively inhibit the activity of ALK when activating mutations are present within its kinase domain, as with the F1174L mutation...
2016: Scientific Reports
https://www.readbyqxmd.com/read/26221861/mucoepidermoid-carcinoma-in-children-a-single-institutional-experience
#4
Piti Techavichit, M John Hicks, Dolores H López-Terrada, Norma M Quintanilla, R Paul Guillerman, Stephen F Sarabia, Hadi Sayeed, Jed G Nuchtern, Arnold C Paulino, Jodi A Muscal, M Fatih Okcu, Murali Chintagumpala
PURPOSE AND OBJECTIVE: To determine the clinicopathologic and molecular features and outcome of children with mucoepidermoid carcinoma (MEC). METHODS: A retrospective analysis of clinical and histopathologic findings was performed in patients with MEC diagnosed at Texas Children's Cancer Center between 2000 and 2014. RESULTS: Ten female and four male patients with median age 12 years (range 7-19 years) were included in the study. Tumors involved major salivary glands, minor salivary glands of the palate, and the tracheobronchial tree...
January 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/24962521/phase-1-evaluation-of-ezn-2208-a-polyethylene-glycol-conjugate-of-sn38-in-children-adolescents-and-young-adults-with-relapsed-or-refractory-solid-tumors
#5
Robin E Norris, Suzanne Shusterman, Lia Gore, Jodi A Muscal, Margaret E Macy, Elizabeth Fox, Noah Berkowitz, Aby Buchbinder, Rochelle Bagatell
BACKGROUND: EZN-2208 is a water-soluble PEGylated conjugate of the topoisomerase inhibitor SN38, the active metabolite of irinotecan. Compared to irinotecan, EZN-2208 has a prolonged half-life permitting extended exposure to SN38. EZN-2208 has demonstrated clinical tolerability and antitumor activity in adults with advanced solid tumors. This Phase 1 study evaluated the safety, pharmacokinetics, and preliminary antitumor activity of EZN-2208 in children with relapsed or refractory solid tumors...
October 2014: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/24097866/a-phase-i-trial-of-imetelstat-in-children-with-refractory-or-recurrent-solid-tumors-a-children-s-oncology-group-phase-i-consortium-study-advl1112
#6
Patrick A Thompson, Rachid Drissi, Jodi A Muscal, Eshini Panditharatna, Maryam Fouladi, Ashish M Ingle, Charlotte H Ahern, Joel M Reid, Tong Lin, Brenda J Weigel, Susan M Blaney
PURPOSE: Imetelstat is a covalently-lipidated 13-mer thiophosphoramidate oligonucleotide that acts as a potent specific inhibitor of telomerase. It binds with high affinity to the template region of the RNA component of human telomerase (hTERC) and is a competitive inhibitor of telomerase enzymatic activity. The purpose of this study was to determine the recommended phase II dose of imetelstat in children with recurrent or refractory solid tumors. EXPERIMENTAL DESIGN: Imetelstat was administered intravenously more than two hours on days 1 and 8, every 21 days...
December 1, 2013: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/22887890/a-phase-i-trial-of-vorinostat-and-bortezomib-in-children-with-refractory-or-recurrent-solid-tumors-a-children-s-oncology-group-phase-i-consortium-study-advl0916
#7
Jodi A Muscal, Patrick A Thompson, Terzah M Horton, Ashish M Ingle, Charlotte H Ahern, Renee M McGovern, Joel M Reid, Matthew M Ames, Igor Espinoza-Delgado, Brenda J Weigel, Susan M Blaney
BACKGROUND: A pediatric Phase I trial was performed to determine the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetics (PK) of vorinostat and bortezomib, in patients with solid tumors. PROCEDURE: Oral vorinostat was administered on days 1-5 and 8-12 of a 21-day cycle (starting dose 180 mg/m(2) /day with dose escalations to 230 and 300 mg/m(2) /day). Bortezomib (1.3 mg/m(2) i.v.) was administered on days 1, 4, 8, and 11 of the same cycle...
March 2013: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/22669335/additive-effects-of-vorinostat-and-mln8237-in-pediatric-leukemia-medulloblastoma-and-neuroblastoma-cell-lines
#8
Jodi A Muscal, Kathleen A Scorsone, Linna Zhang, Jeffrey A Ecsedy, Stacey L Berg
PURPOSE: Histone deacetylase (HDAC) inhibitors, such as vorinostat, decrease Aurora kinase activity by a variety of mechanisms. Vorinostat and MLN8237, a selective Aurora A kinase inhibitor, disrupt the spindle assembly and the mitotic checkpoint at different points, suggesting that the combination could have increased antitumor activity. The purpose of this study was to determine the cytotoxicity of vorinostat and MLN8237 in pediatric tumor cell lines. METHODS: Cell survival was measured after 72 h of drug treatment using a modified methyl tetrazolium assay...
February 2013: Investigational New Drugs
https://www.readbyqxmd.com/read/22109830/plasma-and-cerebrospinal-fluid-pharmacokinetics-of-thalidomide-and-lenalidomide-in-nonhuman-primates
#9
Jodi A Muscal, Yongkai Sun, Jed G Nuchtern, Robert C Dauser, Leticia H McGuffey, Brian W Gibson, Stacey L Berg
PURPOSE: Thalidomide, originally developed as a sedative, was subsequently identified to have antiangiogenic properties. Lenalidomide is an antiangiogenic and immunomodulatory agent that has been utilized in the treatment of patients with brain tumors. We studied the pharmacokinetics and cerebrospinal fluid (CSF) penetration of thalidomide and lenalidomide in a nonhuman primate model. METHODS: A dose of 50 mg of thalidomide or 20 mg of lenalidomide was administered once orally to each of three rhesus monkeys...
April 2012: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/19526240/plasma-and-cerebrospinal-fluid-pharmacokinetics-of-abt-888-after-oral-administration-in-non-human-primates
#10
Jodi A Muscal, Patrick A Thompson, Vincent L Giranda, Brian D Dayton, Joy Bauch, Terzah Horton, Leticia McGuffey, Jed G Nuchtern, Robert C Dauser, Brian W Gibson, Susan M Blaney, Jack M Su
PURPOSE: ABT-888 inhibits poly(ADP-ribose) polymerase (PARP) and may enhance the efficacy of chemotherapy and radiation in CNS tumors. We studied the plasma and cerebrospinal fluid (CSF) pharmacokinetics (PK) of ABT-888 in a non-human primate (NHP) model that is highly predictive of human CSF penetration. METHODS: ABT-888, 5 mg/kg, was administered orally to three NHPs. Serial blood and CSF samples were obtained. Plasma and CSF concentrations of ABT-888 were measured using LC/MS/MS, and the resulting concentration versus time data were evaluated using non-compartmental and compartmental PK methods...
February 2010: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/18485616/changes-mimicking-new-leptomeningeal-disease-after-intensity-modulated-radiotherapy-for-medulloblastoma
#11
Jodi A Muscal, Jeremy Y Jones, Arnold C Paulino, Alison A Bertuch, Jack Su, Shiao Y Woo, Donald H Mahoney, Murali Chintagumpala
PURPOSE: Acute and late changes in magnetic resonance imaging of the pediatric brain have been described after radiotherapy (RT). We report the post-RT neuroimaging changes in the posterior fossa after intensity-modulated RT (IMRT) in children with medulloblastoma and contrast them with those of leptomeningeal disease. METHODS AND MATERIALS: We performed a retrospective review of 53 consecutive children with medulloblastoma who were treated with craniospinal RT followed by IMRT to the posterior fossa and chemotherapy between 1997 and 2006...
January 1, 2009: International Journal of Radiation Oncology, Biology, Physics
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"